The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Death Signaling

Background:

• Tumor cells often evade apoptosis induced by tumor necrosis factor α (TNFα).
• Identifying mechanisms of resistance is crucial for developing effective cancer therapies.

Purpose of the Study:

• To investigate the role of MAP3 kinase Tumor Progression Locus-2 (TPL2) in TNFα-induced apoptosis resistance.
• To explore TPL2 as a potential therapeutic target in cancer treatment.

Main Methods:

• Utilized TPL2 knockdown (siTPL2) in combination with TNFα treatment.
• Investigated receptor-interacting serine/threonine-protein kinase 1 (RIPK1)-dependent and -independent pathways.
• Analyzed molecular events including caspase-8 activation, miR-21-5p, and cFLIP expression.
• Compared gene expression profiles of treatment-sensitive and -resistant cell lines.

Main Results:

• TPL2 knockdown combined with TNFα induced synthetic lethality in a subset of tumor cell lines.
• This synthetic lethality was mediated by both RIPK1-dependent and -independent mechanisms.
• Wild-type TPL2, but not its kinase-dead mutant, rescued the synthetic lethality phenotype.
• TPL2-dependent caspase-8 activation, downstream of miR-21-5p and cFLIP, was a key event.
• Distinct gene expression profiles clustered cell lines into sensitive and resistant groups.

Conclusions:

• TPL2 plays a significant role in protecting certain tumor cells from TNFα-induced apoptosis.
• Targeting TPL2 in combination with TNFα represents a potential synthetic lethality strategy.
• Gene expression profiling shows promise for developing predictive tools for treatment sensitivity.